Global Tinea Corporis Drugs Market is valued at approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Tinea corporis is a fungal infection that affects the upper layer of the skin. It can occur or be produced in any part of the body, but it is most commonly found on the legs and arms, particularly in the glabrous skin. Tinea corporis, also known as ringworm, appears on the skin as a ring structure. Trichophyton rubrum, Microsporum canis, and Epidermophyton floccosum are the fungi that cause tinea corporis. The increasing incidence of fungal infections and rising demand for antifungal drugs are key factors driving the market growth.
As per Centers for Disease Control & Prevention (CDC) estimates - as of 2019, fungal diseases resulted in more than 75,000 hospitalizations and around 9 million outpatient visits occur every year for fungal diseases. Also, rising expansion of e-pharmacies and growing healthcare spending worldwide would create lucrative growth opportunities for the market over the projected period. For instance - as per Statista - In 2021, the global e-pharma market was estimated at USD 1 billion, and it is projected to grow to USD 4.8 billion by the year 2031. However, high cost of Tinea Corporis Drugs and stringent drug approval process hinder the market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global Tinea Corporis Drugs Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the increasing incidence of fungal diseases of skin as well as rising healthcare spending in the region. Whereas Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, and increasing investment towards new product development from leading market players in the region.
Major market players included in this report are:
- Novartis AG (Switzerland)
- Endo International Inc (Ireland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Glenmark Pharmaceuticals Ltd (India)
- Cipla Inc (India)
- Dr Reddy's Laboratories Ltd (India)
- Abbott (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Pfizer Inc (U.S.)
- Zydus Group (India)
Recent Developments in the Market:
- On May 16, 2022 - Shionogi & Co., Ltd. and F2G Ltd. Entered into a strategic collaboration to develop and commercialize the new antifungal agent olorofim for invasive fungal infections in European and Asian markets. This new agent Olorofim is a novel oral antifungal therapy developed by F2G to treat invasive aspergillosis (IA) and other rare mold infections.
Global Tinea Corporis Drugs Market Report Scope:
- Historical Data: 2019-2020-2021
- Base Year for Estimation: 2021
- Forecast period: 2022-2029
- Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
- Segments Covered: Drugs, Route of Administration, End-Users, Distribution Channel, Region
- Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
- Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.
By Drugs
By Route of Administration
By End-Users
- Hospitals
- Homecare
- Specialty Clinics
By Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
By Region:
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Spain
- Italy
- ROE
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- RoAPAC
- Latin America
- Brazil
- Mexico
- RoLA
- Rest of the World
Table of Contents
Chapter 1. Executive Summary
- 1.1. Market Snapshot
- 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
- 1.2.1. Tinea Corporis Drugs Market, by Region, 2019-2029 (USD Billion)
- 1.2.2. Tinea Corporis Drugs Market, by Drugs, 2019-2029 (USD Billion)
- 1.2.3. Tinea Corporis Drugs Market, by Route of Administration, 2019-2029 (USD Billion)
- 1.2.4. Tinea Corporis Drugs Market, by End-Users, 2019-2029 (USD Billion)
- 1.2.5. Tinea Corporis Drugs Market, by Distribution Channel, 2019-2029 (USD Billion)
- 1.3. Key Trends
- 1.4. Estimation Methodology
- 1.5. Research Assumption
Chapter 2. Global Tinea Corporis Drugs Market Definition and Scope
- 2.1. Objective of the Study
- 2.2. Market Definition & Scope
- 2.2.1. Scope of the Study
- 2.2.2. Industry Evolution
- 2.3. Years Considered for the Study
- 2.4. Currency Conversion Rates
Chapter 3. Global Tinea Corporis Drugs Market Dynamics
- 3.1. Tinea Corporis Drugs Market Impact Analysis (2019-2029)
- 3.1.1. Market Drivers
- 3.1.1.1. Increasing incidence of fungal infections
- 3.1.1.2. Growing demand for antifungal drugs
- 3.1.2. Market Challenges
- 3.1.2.1. High Cost of Tinea Corporis Drugs
- 3.1.2.2. Stringent drug approval process
- 3.1.3. Market Opportunities
- 3.1.3.1. Rising expansion of e-pharmacies
- 3.1.3.2. Growing healthcare spending worldwide
Chapter 4. Global Tinea Corporis Drugs Market Industry Analysis
- 4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
- 4.3. PEST Analysis
- 4.3.1. Political
- 4.3.2. Economical
- 4.3.3. Social
- 4.3.4. Technological
- 4.4. Top investment opportunity
- 4.5. Top winning strategies
- 4.6. Industry Experts Prospective
- 4.7. Analyst Recommendation & Conclusion
Chapter 5. Risk Assessment: COVID-19 Impact
- 5.1. Assessment of the overall impact of COVID-19 on the industry
- 5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Tinea Corporis Drugs Market, by Drugs
- 6.1. Market Snapshot
- 6.2. Global Tinea Corporis Drugs Market by Drugs, Performance - Potential Analysis
- 6.3. Global Tinea Corporis Drugs Market Estimates & Forecasts by Drugs 2019-2029 (USD Billion)
- 6.4. Tinea Corporis Drugs Market, Sub Segment Analysis
- 6.4.1. Antifungal
- 6.4.2. Others
Chapter 7. Global Tinea Corporis Drugs Market, by Route of Administration
- 7.1. Market Snapshot
- 7.2. Global Tinea Corporis Drugs Market by Route of Administration, Performance - Potential Analysis
- 7.3. Global Tinea Corporis Drugs Market Estimates & Forecasts by Route of Administration 2019-2029 (USD Billion)
- 7.4. Tinea Corporis Drugs Market, Sub Segment Analysis
- 7.4.1. Oral
- 7.4.2. Topical
- 7.4.3. Parenteral
Chapter 8. Global Tinea Corporis Drugs Market, by End-Users
- 8.1. Market Snapshot
- 8.2. Global Tinea Corporis Drugs Market by End-Users, Performance - Potential Analysis
- 8.3. Global Tinea Corporis Drugs Market Estimates & Forecasts by End-Users 2019-2029 (USD Billion)
- 8.4. Tinea Corporis Drugs Market, Sub Segment Analysis
- 8.4.1. Hospitals
- 8.4.2. Homecare
- 8.4.3. Specialty Clinics
Chapter 9. Global Tinea Corporis Drugs Market, by Distribution Channel
- 9.1. Market Snapshot
- 9.2. Global Tinea Corporis Drugs Market by Distribution Channel, Performance - Potential Analysis
- 9.3. Global Tinea Corporis Drugs Market Estimates & Forecasts by Distribution Channel 2019-2029 (USD Billion)
- 9.4. Tinea Corporis Drugs Market, Sub Segment Analysis
- 9.4.1. Hospital Pharmacy
- 9.4.2. Online Pharmacy
- 9.4.3. Retail Pharmacy
Chapter 10. Global Tinea Corporis Drugs Market, Regional Analysis
- 10.1. Tinea Corporis Drugs Market, Regional Market Snapshot
- 10.2. North America Tinea Corporis Drugs Market
- 10.2.1. U.S. Tinea Corporis Drugs Market
- 10.2.1.1. Drugs breakdown estimates & forecasts, 2019-2029
- 10.2.1.2. Route of Administration breakdown estimates & forecasts, 2019-2029
- 10.2.1.3. End-Users breakdown estimates & forecasts, 2019-2029
- 10.2.1.4. Distribution Channel breakdown estimates & forecasts, 2019-2029
- 10.2.2. Canada Tinea Corporis Drugs Market
- 10.3. Europe Tinea Corporis Drugs Market Snapshot
- 10.3.1. U.K. Tinea Corporis Drugs Market
- 10.3.2. Germany Tinea Corporis Drugs Market
- 10.3.3. France Tinea Corporis Drugs Market
- 10.3.4. Spain Tinea Corporis Drugs Market
- 10.3.5. Italy Tinea Corporis Drugs Market
- 10.3.6. Rest of Europe Tinea Corporis Drugs Market
- 10.4. Asia-Pacific Tinea Corporis Drugs Market Snapshot
- 10.4.1. China Tinea Corporis Drugs Market
- 10.4.2. India Tinea Corporis Drugs Market
- 10.4.3. Japan Tinea Corporis Drugs Market
- 10.4.4. Australia Tinea Corporis Drugs Market
- 10.4.5. South Korea Tinea Corporis Drugs Market
- 10.4.6. Rest of Asia Pacific Tinea Corporis Drugs Market
- 10.5. Latin America Tinea Corporis Drugs Market Snapshot
- 10.5.1. Brazil Tinea Corporis Drugs Market
- 10.5.2. Mexico Tinea Corporis Drugs Market
- 10.5.3. Rest of Latin America Tinea Corporis Drugs Market
- 10.6. Rest of The World Tinea Corporis Drugs Market
Chapter 11. Competitive Intelligence
- 11.1. Top Market Strategies
- 11.2. Company Profiles
- 11.2.1. Novartis AG (Switzerland)
- 11.2.1.1. Key Information
- 11.2.1.2. Overview
- 11.2.1.3. Financial (Subject to Data Availability)
- 11.2.1.4. Product Summary
- 11.2.1.5. Recent Developments
- 11.2.2. Endo International Inc (Ireland)
- 11.2.3. Teva Pharmaceutical Industries Ltd (Israel)
- 11.2.4. Glenmark Pharmaceuticals Ltd (India)
- 11.2.5. Cipla Inc (India)
- 11.2.6. Dr Reddy's Laboratories Ltd (India)
- 11.2.7. Abbott (U.S.)
- 11.2.8. F. Hoffmann-La Roche Ltd (Switzerland)
- 11.2.9. Pfizer Inc (U.S.)
- 11.2.10. Zydus Group (India)
Chapter 12. Research Process
- 12.1. Research Process
- 12.1.1. Data Mining
- 12.1.2. Analysis
- 12.1.3. Market Estimation
- 12.1.4. Validation
- 12.1.5. Publishing
- 12.2. Research Attributes
- 12.3. Research Assumption